Dear Belgian Thyroid Club member,
We are setting up an academic interventional study to investigate therapy with 3,5,3’-triiodothyroacetic acid (TRIAC) in patients with resistance to thyroid hormone, caused by mutations in the thyroid hormone receptor β (THRB). TRIAC is a known T3 analogue with higher affinity for THRB. Besides the impact on the biochemical profile, the impact on neuropsychological and endocrine manifestations and on cardiometabolic risk factors will be studied.
In order to get an idea of the prevalence in Belgium and potential inclusion numbers, we would highly appreciate your answer to the following 3 questions in an e-mail reply to anne.rochtus@uzleuven.be
1/ How many patients with thyroid hormone resistance do you follow approximately in your center?
a. 0 ; b. 1-5 ; c. 5-10 ; d. > 10
2/ are you interested to collaborate with an interventional study with TRIAC?
3/ in which center do you work?
Kind regards,
Anne Rochtus, Pediatric Endocrinology, University Hospital Leuven
Brigitte Decallonne, Adult Endocrinology, University Hospital Leuven